Febuxostat, a novel non–purine analogue inhibitor of xanthine oxidase, improves systolic hypertension and kidney tubulointerstitial injury in HN rats likely through attenuation of ER stress and MUC crystal deposition in tubules. Here, XDH is linked to hypertensive disorder.